Quintrio
Home

PHARMACEUTICAL PREPARATIONS

TuHURA Biosciences, Inc. Common Stock

HURA

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Last trade $1.33
Day change $0.00 (0.00%)
Day range $1.30 – $1.44
Volume 344,163
Market cap $87M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$87.46M
Price / earnings
—
Price / book
4.73×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.34×

Profitability

Earnings per share
-$0.47
Return on assets
-96.49%
Return on equity
-165.57%
Dividend yield
0.01%

Liquidity and leverage

Debt / equity
0.28×
Current ratio
0.18×
Quick ratio
0.18×
Cash ratio
0.11×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$29.9M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for HURA, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0
Selling, general and administrative$2.14M$2.3M-$1.56M$1.76M$1.86M$2.02M$1.28M
Research and development$6.62M$5.23M$6.06M$4.97M$4.93M$4.58M$3.98M
Total operating expenses$8.76M$7.53M$8.17M$6.73M$9.88M$7.02M$5.69M
Operating income-$8.76M-$7.53M-$8.17M-$6.73M-$9.88M-$7.02M-$5.69M
Interest expense-$467.63K-$27.97K-$608.75K-$16.53K$0$0-$522.84K
Income before taxes-$9.22M-$7.54M-$6.76M-$7.1M-$9.52M-$6.66M-$6M
Income taxes$0$0$0$0$0$0$0
Net income-$9.22M-$7.54M-$6.76M-$7.1M-$9.52M-$6.66M-$6M
Net income attributable to common shareholders-$9.23M-$7.54M-$6.76M-$7.1M-$9.53M-$6.67M-$6M
EBITDA-$8.74M-$7.51M-$4.47M-$6.71M-$6.78M-$6.58M-$5.24M
Basic earnings per share-$0.14-$0.13-$0.13-$0.14-$0.21-$0.15-$0.16
Diluted earnings per share-$0.14-$0.13-$0.13-$0.14-$0.21-$0.15-$0.16

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

TuHURA R&D Jumps 75% in Q2

TuHURA Biosciences advanced its immuno-oncology pipeline in Q2 2025, launching a Phase 3 trial for IFx-2.0 in Merkel cell carcinoma and completing the Kineta acquisition. The company raised $15.5 million in equity financing to support ongoing clinical development.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 18, 20242-for-1stock dividend